ArticleDiscover oncology2026
Epididymal leiomyosarcoma: a case report.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpididymal leiomyosarcoma is a rare, malignant neoplasm (Fisher et al. in Am J Surg Pathol 25(9):1143–9, 2001) characterized by rapid growth and aggressive behavior. Over the past decade, fewer than 30 cases of epididymal leiomyosarcoma have been reported globally. CASE PRESENTATION: In 2024, a male presented to the Fourth Affiliated Hospital of Zhejiang Universityl with a left scrotal mass. The patient underwent scrotal ultrasound and pelvic MRI, initially diagnosed with a hypervascular tumor of the epididymis; however, the precise nature of the tumor remained indeterminate before surgery. Following radical orchiectomy, postoperative pathology confirmed the diagnosis of epididymal leiomyosarcoma.
conclusionAlthough epididymal leiomyosarcoma represents a rare entity, it should be included in the differential diagnosis when patients present with a progressive scrotal mass demonstrating characteristic imaging features of diffusion restriction, heterogeneous hypoechogenicity, and hypervascularity. Notably, despite the well-demarcated contours and regular configuration of early-stage lesions, radical orchiectomy should be strongly recommended over simple epididymectomy given the tumor’s aggressive biological behavior. Simple epididymectomy is associated with higher recurrence rates. Long-term, rigorous surveillance remains paramount for disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.